Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Pfizer Tilrekimig Data Support TSLP Role in Atopic Dermatitis, UBS Says

Pfizer Tilrekimig Data Support TSLP Role in Atopic Dermatitis, UBS Says

MT newswireMT newswire2026/10/02 16:54
12:54 PM EDT, 10/02/2026 (MT Newswires) -- Pfizer's (PFE) phase II data for its monthly IL-4, IL-13 and TSLP drug tilrekimig showed placebo-adjusted EASI-75 responses of about 40% to 50%, supporting the potential benefit of adding TSLP inhibition in atopic dermatitis, UBS Securities said. The investment firm said in a note Thursday that the results appear competitive with next-generation agents and above Dupixent on a placebo-adjusted EASI-75 basis. The firm also noted low rates of eye-related adverse events and consistent trends in itch reduction, while the study's placebo response was lower than in some comparable trials. Pfizer has started phase III studies of tilrekimig in asthma and atopic dermatitis, including a head-to-head study against Dupixent. The program could become a meaningful commercial player if successful, according to the note. UBS has a neutral rating on the company's stock, with a $27 price target. Shares of Pfizer were down 2% in Friday afternoon trading. Price: 27.55, Change: -0.57, Percent Change: -2.04
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Tobacco and alcohol stocks lead gains in the consumer staples sector

On October 8, Thursday, Philip Morris International (PM.N) became the top gainer in the S&P 500 Consumer Staples sector (.SPLRCS), followed by alcoholic beverage company Constellation Brands (STZ.N) and Altria Group (MO.N), both ranking among the day's biggest gainers. Shares of Philip Morris International (PM), a supplier of cigarettes and smoke-free nicotine products, rose about 4% to $200.89, set for a fourth consecutive session of gains and marking the largest single-day increase since July 16. Marlboro cigarette maker Altria gained 2.9% to $71.36. Earlier, British peer Imperial Brands (IMB.L) said it expects to meet its full-year guidance and announced a £1.5 billions ($1.98 billions) share buyback plan, as robust growth in tobacco alternatives helped offset declining cigarette sales. STZ, which produces beer, wine, and spirits, rose over 3% to $122.35 on the second trading day after releasing its quarterly report, despite several brokerages lowering their price targets. JPMorgan, however, raised its target from $133 to $136. Cetera Chief Investment Officer Gene Goldman noted on Thursday that there is “a rotation from growth stocks to defensive stocks” in the market, adding that “rising yields and wider credit spreads are putting pressure on AI and growth stocks.” He also pointed out that valuations in the sector are improving. Over the past three months, the sector has underperformed the broader S&P 500, falling 1% versus the benchmark’s 3.9% rise. Among the five S&P sectors that did not decline on Thursday, the Consumer Staples Index posted the second-largest gain, up 1.6%.

路透社•2026/10/08 17:06

US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46

SuperX AI Technology's stock price declined, falling more than 2.5% at one point.

智通财经•2026/10/08 16:11